Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Immunoglobulin a Nephropathy (IgAN)”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06137768
What this trial is testing

A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

Who this might be right for
Primary IgA Nephropathy
Chengdu Suncadia Medicine Co., Ltd. 123
Large-scale testing (Phase 3)Looking for participantsNCT07024563
What this trial is testing

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Who this might be right for
IgANIgAVNImmunoglobulin A Nephropathy+3 more
Alexion Pharmaceuticals, Inc. 24
Post-approval studies (Phase 4)Looking for participantsNCT06676384
What this trial is testing

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

Who this might be right for
IgA NephropathyRenal Insufficiency, ChronicIgA Vasculitis+1 more
Christian Medical College, Vellore, India 585
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07354932
What this trial is testing

SHR-2173 in Participants With Primary IgA Nephropathy

Who this might be right for
Primary IgA Nephropathy
Guangdong Hengrui Pharmaceutical Co., Ltd 84
Not applicableUnknownNCT02829164
What this trial is testing

Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region

Who this might be right for
Tonsillectomy
University Hospital, Strasbourg, France 20
Large-scale testing (Phase 3)Study completedNCT05534919
What this trial is testing

Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

Who this might be right for
Primary Immunoglobulin a Nephropathy (IgAN)
Everest Medicines (Singapore) Pte. Ltd. 21
Large-scale testing (Phase 3)Study completedNCT04578834
What this trial is testing

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Who this might be right for
IgA Nephropathy
Novartis Pharmaceuticals 518
Post-approval studies (Phase 4)UnknownNCT05824390
What this trial is testing

A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

Who this might be right for
IgA Nephropathy
XIEJINGYUAN 116
Large-scale testing (Phase 3)Active Not RecruitingNCT05799287
What this trial is testing

Telitacicept for IgA Nephropathy (TELIGAN)

Who this might be right for
Primary IgA Nephropathy
RemeGen Co., Ltd. 318
Post-approval studies (Phase 4)Study completedNCT02351752
What this trial is testing

Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study

Who this might be right for
Primary IgA Nephropathy
LLiu 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06687174
What this trial is testing

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Who this might be right for
IgA Nephropathy (IgAN)
Wuhan Createrna Science and Technology Co., Ltd 72
Testing effectiveness (Phase 2)Study completedNCT01738035
What this trial is testing

The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease

Who this might be right for
Primary IgA Nephropathy
Calliditas Therapeutics AB 150
Not applicableLooking for participantsNCT06926244
What this trial is testing

RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)

Who this might be right for
IgA Nephropathy (IgAN)
Assistance Publique - Hôpitaux de Paris 800
Early research (Phase 1)Study completedNCT04887532
What this trial is testing

A Trial of HR19042 Capsule in Healthy Chinese Subjects

Who this might be right for
Primary IgA Nephropathy
Jiangsu HengRui Medicine Co., Ltd. 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06786338
What this trial is testing

SGB-9768 in Patients with Complement-mediated Kidney Diseases

Who this might be right for
IgA Nephropathy (IgAN)C3 GlomerulopathyIC-MPGN
Suzhou Sanegene Bio Inc. 38
Testing effectiveness (Phase 2)Looking for participantsNCT07305974
What this trial is testing

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

Who this might be right for
IgA Nephropathy (IgAN)
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. 30
Not applicableLooking for participantsNCT04858724
What this trial is testing

The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)

Who this might be right for
IgA Nephropathy
Ruijin Hospital 2,000
Very early researchNot Yet RecruitingNCT06690359
What this trial is testing

IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients

Who this might be right for
IgA NephropathyMembranous Nephropathy
Beijing Immunochina Medical Science & Technology Co., Ltd. 12
Testing effectiveness (Phase 2)Study completedNCT04291781
What this trial is testing

RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

Who this might be right for
Primary IgA Nephropathy
RemeGen Co., Ltd. 44
Large-scale testing (Phase 3)Looking for participantsNCT04557462
What this trial is testing

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Who this might be right for
Primary IgA Nephropathy
Novartis Pharmaceuticals 540
Load More Results